$3.270
+0.041 (+1.24%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
SONM Prediction & Forecast by Similar Chart Analysis
Alphio's SONM stock price prediction model matches the current DNA X Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $3.25 (-0.52%). The 1-week path is $3.19 (-2.59%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy DNA X Inc Stock?
Sonim Technologies Inc is not a good buy right now due to significant financial losses and a declining stock price. The current price is $3.27, and the stock has dropped 80.61% over the past year. Additionally, the RSI is at 33.107, indicating the stock is oversold but also reflects a lack of buying momentum. The forward P/E ratio of 3.1676 suggests potential undervaluation, but the overall financial health is poor, with a net income loss of $12.47 million in the last reported quarter. The main risk is the lack of revenue, as the company reported zero revenue in multiple quarters, which raises concerns about its sustainability.
SONM stock price ended at $3.27 on Friday, after rising +1.24%
DNA X Inc (SONM) last closed at $3.27, gaining +1.24%. These facts feed the 1-day and 1-week SONM price prediction above.
Forecast Drivers
DNA X Inc (SONM) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches SONM, ranked by similarity.
Seasonality analysis for SONM
Historically the probability of a positive October return for SONM is 22.03%. June offers the highest probability of a positive month at 51.67%, while November is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.